Wall Street Zen Downgrades Telix Pharmaceuticals (NASDAQ:TLX) to Sell

Telix Pharmaceuticals (NASDAQ:TLX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Sunday.

Other equities analysts have also recently issued research reports about the company. Citigroup lifted their price target on Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $21.13.

Telix Pharmaceuticals Stock Up 0.3%

Shares of TLX stock opened at $7.87 on Friday. Telix Pharmaceuticals has a one year low of $6.28 and a one year high of $20.00. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The stock has a 50-day moving average of $7.32 and a 200-day moving average of $8.76.

Telix Pharmaceuticals (NASDAQ:TLX) last released its quarterly earnings data on Friday, February 20th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). Analysts anticipate that Telix Pharmaceuticals will post 0.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of hedge funds have recently bought and sold shares of TLX. Russell Investments Group Ltd. bought a new position in Telix Pharmaceuticals during the second quarter worth $975,000. Jane Street Group LLC purchased a new stake in shares of Telix Pharmaceuticals in the second quarter worth approximately $564,000. IHT Wealth Management LLC bought a new position in Telix Pharmaceuticals during the 2nd quarter valued at $213,000. Rhumbline Advisers lifted its position in shares of Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after purchasing an additional 1,392 shares in the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in shares of Telix Pharmaceuticals in the 3rd quarter worth approximately $243,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.